Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALFENTA vs MOTRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Non-selective COX-1 and COX-2 inhibitor, reducing prostaglandin synthesis.
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Primary dysmenorrhea,Fever reduction
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Ibuprofen (Motrin) 200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day for acute pain, and 2400 mg/day for chronic use.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Terminal elimination half-life approximately 2-4 hours in adults with normal renal function; prolonged in elderly and patients with renal impairment (up to 6-8 hours). No significant accumulation occurs with regular dosing.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Hepatic via CYP2C9 and glucuronidation; minor via CYP2C8.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Renal excretion of conjugated metabolites (approximately 70-80% as glucuronide and sulfate conjugates); less than 10% excreted unchanged. Biliary/fecal elimination accounts for about 10-20%.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Highly protein-bound (approximately 99%) primarily to albumin.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Approximately 0.1-0.2 L/kg (range 0.1-0.2 L/kg); indicative of limited tissue distribution due to high protein binding. Larger Vd in neonates (0.3-0.4 L/kg).
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Oral immediate-release: 80-100%; oral extended-release: approximately 85-90% relative to immediate-release; intravenous: 100%; topical (e.g., gel): 3-8% systemic absorption.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
GFR 30-59 m L/min: use minimum effective dose, monitor renal function; GFR <30 m L/min: avoid use; dialysis: not removed by hemodialysis, avoid use.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Child-Pugh Class A: no adjustment; Class B: use with caution, reduce dose by 50%; Class C: avoid use.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Children 6 months to 12 years: 5-10 mg/kg/dose every 6-8 hours; maximum 40 mg/kg/day, not to exceed adult maximum; for fever >39°C, 10 mg/kg/dose; available as oral suspension (100 mg/5 m L).
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
Initiate at the lowest effective dose (e.g., 200-400 mg every 6-8 hours), maximum 3200 mg/day; monitor for GI bleeding and renal impairment; avoid prolonged use due to increased cardiovascular and GI risks.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Increased risk of cardiovascular thrombotic events; risk of serious GI adverse events including bleeding, ulceration, and perforation; renal toxicity; hypertension; anaphylactoid reactions; serious skin reactions; hematologic toxicity; avoid in advanced renal disease.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Hypersensitivity to ibuprofen or other NSAIDs; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; active GI bleeding; history of recurrent peptic ulcer disease; severe heart failure.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Concurrent alcohol consumption increases risk of GI bleeding and ulceration. Avoid high-sodium foods to minimize fluid retention and potential exacerbation of hypertension. Grapefruit juice may slightly reduce rate of absorption but is not clinically significant.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Motrin (ibuprofen) is an NSAID. First trimester: Risk of miscarriage and congenital malformations, particularly cardiac defects, with use. Second trimester: Generally considered safer but avoid prolonged use due to potential for oligohydramnios. Third trimester: Contraindicated after 20 weeks due to risk of premature ductus arteriosus closure, oligohydramnios, and neonatal complications including pulmonary hypertension and renal impairment.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
Ibuprofen is excreted into breast milk in very small amounts. The M/P ratio is approximately 0.01. The relative infant dose is less than 1% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but avoid high doses or prolonged use.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
No dose adjustment is recommended in pregnancy; however, use should be restricted to the lowest effective dose for the shortest duration possible. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce plasma concentrations, but no formal dose adjustment studies exist. Avoid use after 20 weeks gestation.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
For acute pain, use lowest effective dose for shortest duration to minimize GI and renal risks. Administer with food or milk to reduce GI irritation. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min) or active peptic ulcer disease. Ibuprofen can mask fever, making infection detection difficult. Caution in asthma patients as it may precipitate bronchospasm. Monitor blood pressure in hypertensive patients due to potential for fluid retention.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
Take with food or milk to prevent stomach upset.,Do not exceed 1200 mg per day for OTC use (adults) or as directed by your doctor.,Avoid alcohol while taking this medication to reduce risk of stomach bleeding.,Stop use and consult doctor if symptoms persist for more than 10 days (pain) or 3 days (fever).,Do not take with other NSAIDs or pain relievers without consulting your healthcare provider.,Notify your doctor if you have a history of heart disease, high blood pressure, or stomach ulcers.
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALFENTA vs MOTRIN, answered by our medical review team.
ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. MOTRIN is a NSAID Analgesic that works by Non-selective COX-1 and COX-2 inhibitor, reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALFENTA and MOTRIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. The standard adult dose of MOTRIN is: Ibuprofen (Motrin) 200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day for acute pain, and 2400 mg/day for chronic use.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALFENTA and MOTRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. MOTRIN is classified as Category C. Motrin (ibuprofen) is an NSAID. First trimester: Risk of miscarriage and congenital malformations, particularly cardiac defects, with use. Second trimester: Generally considered sa. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.